Yonsei University: Diabetes Mellitus, Type 2 trials

The registry lists 18 Diabetes Mellitus, Type 2 studies with Yonsei University as lead sponsor. 4 are open to participants now and 0 have results posted.

Phase 2 1Phase 4 12No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 InhibitorsNot yet recruitingNCT07108985Phase 4
• A Prospective Trial of Enavogliflozin to Evaluate Cardio-renal Outcome in Type 2 Diabetes Mellitus PatientsRecruitingNCT06642623Phase 4
• A Prospective Cohort Study for Establishing Clinical Excellence in Patients With Newly Diagnosed Type 1 and Type 2 Diabetes and PrediabetesNot yet recruitingNCT05401708
• The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes PatientsRecruitingNCT03059069Phase 4
• SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort StudyActive, not recruitingNCT07198191
• Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 DiabetesStatus unknownNCT04584242Phase 4
• A Randomized, Placebo-controlled Clinical Trial of Teneligliptin as Quadruple Oral Combination Therapy for Type 2 DM After Failure of an Oral Triple Anti-diabetic RegimenCompletedNCT04446026Phase 4
• Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic RegimenCompletedNCT04013581Phase 4
• To Evaluate the Effect of Nesinaact on Non-alcoholic Steatohepatitis Through MRI and Liver Fibroscan in Patients With Type 2 DiabetesStatus unknownNCT03950505Phase 4
• Antidiabetic Drugs for Steatotic Liver DiseaseCompletedNCT03646292Phase 4
• Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including DiabetesStatus unknownNCT03204799
• Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 DiabetesCompletedNCT02964572Not applicable
• Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and PioglitazoneCompletedNCT02875821Phase 4
• Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic PatientsCompletedNCT02751398Phase 4
• Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative StressCompletedNCT02650830
• A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLDCompletedNCT02285205Phase 4
• Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 DiabetesCompletedNCT02191644Phase 2
• The Effect of Prostaglandin I2 on the Endothelial Cell Function Disorder in Type 2 Diabetes Mellitus PatientsCompletedNCT01061060Phase 4